首页> 外文期刊>Diabetes therapy >Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden
【24h】

Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden

机译:瑞典胰高血糖素样肽-1激动剂与二肽基肽酶-4抑制剂或中性鱼精蛋白哈格多恩基础胰岛素作为二甲双胍在瑞典2型糖尿病中的应用的成本-效用分析

获取原文
           

摘要

Introduction This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c)?≤?7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin. Methods A previously developed cohort model for T2DM was applied over a 35-year time horizon. Data on T2DM patients on metformin monotherapy with HbA1c?>?7% were collected from the Swedish National Diabetes Register. Treatment effects were taken from published studies. Costs and effects were discounted at 3% per annum, and the analysis was conducted from a societal perspective. The robustness of the results was evaluated using one-way and probabilistic sensitivity analyses. Results Treatment with GLP-1 agonists was associated with a discounted incremental benefit of 0.10 and 0.25 quality-adjusted life years (QALYs) and higher discounted costs of Swedish Krona (SEK) 34,865 and SEK 40,802 compared with DPP-4 inhibitors and NPH insulin, respectively. Assuming willingness-to-pay (WTP) of SEK 500,000 per QALY, treatment strategy with GLP-1 agonists was a cost-effective option with incremental cost-effectiveness ratios of SEK 353,172 and SEK 160,618 per QALY gained versus DPP-4 inhibitors and NPH insulin, respectively. The results were most sensitive to incidence rate of moderate/major hypoglycemia and disutilities associated with insulin treatment, body mass index (BMI), and hypoglycemia. Conclusion Assuming a WTP of SEK 500,000 per QALY, treatment strategy with GLP-1 agonists is a cost-effective strategy in comparison to DPP-4 inhibitors and NPH insulin among T2DM patients inadequately controlled with metformin alone in a Swedish setting.
机译:简介本研究旨在评估三种二线治疗策略对瑞典2型糖尿病(T2DM)的糖化血红蛋白(HbA1c)?≤?7%单独使用二甲双胍治疗的患者的成本和收益:胰高血糖素如肽1(GLP-1)受体激动剂,二肽基肽酶4(DPP-4)抑制剂和中性鱼精蛋白Hagedorn(NPH)胰岛素。方法在35年的时间范围内应用先前开发的T2DM队列模型。从瑞典国家糖尿病登记处收集HbA1c≥7%的二甲双胍单药治疗的T2DM患者数据。治疗效果来自已发表的研究。成本和效果折现为每年3%,并且从社会角度进行了分析。使用单向和概率敏感性分析评估结果的稳健性。结果与DPP-4抑制剂和NPH胰岛素相比,使用GLP-1激动剂治疗可带来0.10和0.25质量调整生命年(QALYs)的折现增量收益以及瑞典克朗(SEK)34,865和SEK 40,802的折算成本更高,分别。假设每QALY的支付意愿(WTP)为500,000瑞典克朗,那么GLP-1激动剂的治疗策略是一种具有成本效益的选择,与DPP-4抑制剂和NPH相比,每QALY获得的成本效益比为353,172 SEK和160,618 SEK胰岛素。结果对中/重度低血糖的发生率以及与胰岛素治疗,体重指数(BMI)和低血糖有关的无效性最敏感。结论假设每个QALY的WTP为500,000瑞典克朗,在瑞典环境中,单独使用二甲双胍治疗的T2DM患者与DPP-4抑制剂和NPH胰岛素相比,使用DLP-4激动剂的治疗策略是一种经济有效的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号